Description: This 3.1 Å crystal structure defines the Asn332 glycan-dependent ‘supersite of immune vulnerability’ on HIV-1 gp120, showing how broadly neutralizing antibody PGT135 uses extended CDR loops to penetrate the glycan shield and contact glycans at Asn332, Asn392, and Asn386. The discovery of this extensive antigenic region makes it a prime target for HIV vaccine immunogen design.